Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies.

Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals.

With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

Ariana Pharma has developed an explainable artificial intelligence platform which explores all possible biomarker associations, generating results that can be used directly to design clinical trials and accelerate drug development. Based on the mathematical theories of Formal Concept Analysis and Gallois lattices, the power of the KEM® platform lies in its ability to deliver explainable results from small cohorts. KEM® is also effective at managing contradictions and heterogeneous data, ensuring the identification of relevant and accurate hypotheses that meet the needs of precision medicine.

–  Therapeutic areas: Oncology, CNS, Cardiometabolic, Immunology

–  Based in: Paris (FRANCE)

–  Employees: 11-50

–  Created in: 2003